NVO.WA
NVONORDSK

Healthcare · Drug Manufacturers - General · valued as of 2026-11-03 · statements 2025-12-31

Average Intrinsic Value

535.42B USD

Market Cap

164.88B USD

Margin of Safety

69.2%

Intrinsic / Market Ratio

3.25×

Projections, not exact values. Intrinsic Values are projected from each company's past reports. They show which stocks look cheap compared with the others, not exactly what a stock is worth.

How Each Value Is Built

The screener's three formulas on the reported figures. Each card reads the same way: the value as a sum of numbered terms, each term's calculation opened under it, from the reported figures to the value. The list ranks companies by their plain average over the market cap.

EPV + Growth

262.78B USD

what the normal year's earnings are worth for ever, plus growth that pays

Profit

665.79B USD

15 years of cash the shareholders can take out, and the equity left at year 15

FCFF

677.68B USD

15 years of cash for shareholders and lenders, less what is owed

Intrinsic Value

535.42B USD

the plain average of the three, uncapped, as the screener averages them

Intrinsic Value

535.42B USD

from the sum above

Market Cap

164.88B USD

the price on the date above times the shares

Intrinsic Value ÷ Market Cap

3.25×

the ratio the screener ranks by; Margin of Safety +69.2% (1 − Market Cap ÷ Intrinsic Value)

Each card below builds one of the three values from the reported years.

Earnings power value plus growth: 262.78B USD
What the normal year's operating profit after tax is worth if it lasts for ever, plus what the new investment adds beyond its cost, less the net debt that comes before the shareholders (or plus the net cash).
①EPV (earnings power value)273.32B USD
−②Net Debt Today14.55B USD
+③Growth Value4.02B USD
=Value262.78B USD

EPV of the Operations (NOPAT over WACC)

273.32B USD

Net debt today

-14.55B USD

Growth Value

+4.02B USD

Value

262.78B USD

①EPV (earnings power value)

273.32B USD

②Net Debt Today

14.55B USD

③Growth Value

4.02B USD

Market value

Market Cap164.88B USD

The price on the date above times the shares.

Value vs market

Margin of Safety+37.3%

1 minus the market cap as a share of the value.

Profit value: today's value of the shareholders' equity, from the cash it can pay them (FCFE): 665.79B USD
Fifteen years of free cash flow to equity (FCFE), each brought to today at the cost of equity, plus the equity at year 15 brought to today.
①Present Value of the 15 Years of FCFE487.60B USD
+②Equity at Year 15, Today178.19B USD
=Value665.79B USD
FCFE: the net income left for the shareholders once the business keeps what next year's growth needsEquity reinvestment: the part of the year's net income kept in the business to grow the next year; below zero, capital the business releases to the shareholdersPresent value of the FCFEColoured bars show the FCFE, grey bars the equity reinvestment. With a positive equity reinvestment the two stacked are the year's normalized income; with a negative one the grey is below zero, capital the business releases, and the normalized income is the FCFE plus that negative amount. Shaded, years 6 to 10: the growth falling to its long-run rate and the ROE on new investment falling to the cost of equity. Axes linear.

①Present Value of the 15 Years of FCFE

487.60B USD

②Equity at Year 15, Today

178.19B USD

Market value

Market Cap164.88B USD

The price on the date above times the shares.

Value vs market

Margin of Safety+75.2%

1 minus the market cap as a share of the value.

FCFF value: today's value of the shareholders' equity, from the cash the firm can pay its shareholders and lenders (FCFF): 677.68B USD
Fifteen years of free cash flow to the firm (FCFF), each brought to today at the WACC, plus the invested capital at year 15 brought to today, less the net debt today (or plus the net cash).
①Present Value of the 15 Years of FCFF475.23B USD
+②Invested Capital at Year 15, Today217.00B USD
−③Net Debt Today14.55B USD
=Value677.68B USD
FCFF: the NOPAT left for the shareholders and the lenders once the business reinvests what next year's growth needsReinvestment: the part of the year's NOPAT put back into the business to grow the next year; below zero, capital the business releasesPresent value of the FCFFColoured bars show the FCFF, grey bars the reinvestment. With a positive reinvestment the two stacked are the year's NOPAT; with a negative one the grey is below zero, capital the business releases, and the NOPAT is the FCFF plus that negative amount. Shaded, years 6 to 10: the growth falling to its long-run rate and the ROIC on new investment falling to the WACC. Axes linear.

①Present Value of the 15 Years of FCFF

475.23B USD

②Invested Capital at Year 15, Today

217.00B USD

③Net Debt Today

14.55B USD

Market value

Market Cap164.88B USD

The price on the date above times the shares.

Value vs market

Margin of Safety+75.7%

1 minus the market cap as a share of the value.

The Rates and the Capital the Values Read

The WACC and the cost of equity each value is discounted at, the book value and the net debt each starts from, and the seven quality metrics, from the same run.

WACC: 6.09%
Cost of Equity =Risk-Free Rate 4.50%+Beta 0.34×Market Risk Premium 6.00%= 6.56%

The yearly return the shareholders require for the risk they carry; it is the rate that brings their future cash to today.

Tax Rate for WACC =Tax Provision 4.43B USDPretax Income 20.55B USD= 21.53%

The tax the interest saves.

Interest Expense =EBIT 21.21B USD−Pretax Income 20.55B USD= 662.36M USD

The interest the company paid: EBIT is the profit before tax plus the interest.

Cost of Debt =Interest Expense 662.36M USDTotal Debt 21.43B USD×(1 − Tax Rate for WACC 21.53%)= 2.43%

What the lenders are paid a year after the tax the interest saves.

Debt Weight =Total Debt 21.43B USDMarket Cap + Total Debt 164.88B USD + 21.43B USD= 11.50%

The part of the capital the lenders put in, at market value.

WACC =Equity Weight 88.50%×Cost of Equity 6.56%+Debt Weight 11.50%×Cost of Debt 2.43%= 6.09%

Weighted average cost of capital: the yearly return the shareholders and the lenders together require, weighted by what each puts in; the rate that brings the firm's future cash to today.

Book value and net debt today
Both from the balance sheet of the newest quarter, 2026-06-30.

Total Assets 90.99B USD − Total Liabilities 57.15B USD = Book Value Today 33.84B USD

Total Debt 21.43B USD − Cash and Short-Term Investments 6.88B USD = Net Debt Today 14.55B USD

The book value is what Profit starts from and what stands when a projection is not made; the book value plus the net debt is what FCFF starts from; the net debt comes off Greenwald's and FCFF's values before the shareholders.

Quality metrics
Read beside the value, never a condition for it: every company is valued, and a filter in the list is the reader's choice.
MetricFrom
Share dilutionShares Today ÷ Shares Two Years Back − 1-0.8%at most 5%passes4,424,805,520 / 4,458,287,946
Accrual quality(Operating Cash Flow − Net Income) ÷ Total Assets2.9%at least -10.0%passes(18.75B USD − 16.13B USD) ÷ 90.99B USD
Price to bookMarket Cap ÷ Book Value Today4.87×at most 3×does not pass164.88B USD ÷ 33.84B USD
Operating marginOperating Income ÷ Revenue41.3%above 10.0%passes20.10B USD ÷ 48.66B USD
Revenue growthRevenue ÷ Revenue a Year Before − 120.0%above 10.0%passes48.66B USD / 40.56B USD
Net cash(Cash − Total Debt) ÷ Market Cap-8.9%above -30%passes(6.80B USD − 21.43B USD) ÷ 164.88B USD
Operating efficiencyOperating Income ÷ Gross Profit51.0%above 25.0%passes20.10B USD ÷ 39.40B USD

Market Data

The provider's ratios and the analysts' consensus beside the argument; none of them enters a value.

Share price

146.61 PLN

Enterprise value

748.85B PLN

the provider's own figure

EV / EBITDA

4.31×

Price / book

2.93×

the provider's book

Price / earnings

9.55×

Return on equity

59.8%

the provider's figure, not this page's

Profit margin

35.4%

Revenue growth

2.1%

Analyst target, mean

—

Analysts

—

opinions in the consensus

Financial Statements

The annual lines the screener holds, year by year, in USD at each period's rate; the figures this valuation read are in its calculation above.

USD2022202320242025
Income statement

Revenue

25.40B34.52B40.56B48.66B

Gross profit

21.31B29.21B34.34B39.40B

Operating income

10.74B15.25B17.93B20.10B

EBITDA

operating income before depreciation and amortisation

11.02B17.04B19.19B23.52B

Pretax income

9.91B15.56B17.76B20.55B

Net income

7.97B12.44B14.11B16.13B

Normalized income

net income without one-off items, as the data provider prints it; Profit's line when printed

8.57B12.24B14.22B15.38B

R&D

3.45B4.82B6.71B8.19B
Balance sheet, year end

Total assets

34.62B46.75B65.04B85.48B

Total liabilities

22.64B30.91B44.99B54.92B

Shareholders' equity

the equity the parent's shareholders own, as printed, without minority interest; the book value the values read is total assets less total liabilities, in Book Value and Net Debt above

11.98B15.84B20.04B30.55B

Total debt

3.70B4.01B14.36B20.62B

Cash and equivalents

1.82B2.14B2.19B4.17B

Net PP&E

fixed assets after depreciation

9.57B13.52B22.58B32.81B

Working capital

current assets less current liabilities

-1.83B-4.46B-7.80B-6.80B
Cash flow

Operating cash flow

11.32B16.19B16.90B18.75B

Capital expenditure

paid out, so below zero

-2.12B-5.78B-7.17B-14.19B

Depreciation and amortisation

1.06B1.40B1.19B2.31B

Free cash flow

operating cash flow plus capital expenditure

9.20B10.41B9.73B4.56B